Amicus Therapeutics Stock Statistic Functions Linear Regression Angle
| FOLD Stock | USD 14.36 -0.01 -0.07% |
| Symbol |
Amicus Therapeutics Technical Analysis Modules
Most technical analysis of Amicus Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Amicus from various momentum indicators to cycle indicators. When you analyze Amicus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Amicus Therapeutics Inc
Methodology
Unless otherwise specified, financial data for Amicus Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Amicus (USA Stocks:FOLD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Amicus Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Amicus Therapeutics is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, among others. Updates may occur throughout the day.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | ESG Investing Invested few shares | |
 | Power Assets Invested over 200 shares | |
 | Driverless Cars Invested over 40 shares | |
 | Momentum Invested over 20 shares | |
 | Disruptive Technologies Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Cash Cows Invested few shares |
More Resources for Amicus Stock Analysis
A comprehensive view of Amicus Therapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Amicus Therapeutics Stock. Key reports that frame Amicus Therapeutics Stock are listed below: Quarterly Earnings Growth -0.95 | Earnings Share -0.09 | Revenue Per Share | Quarterly Revenue Growth 0.237 | Return On Assets |